Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

David Camidge

Concepts (590)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Carcinoma, Non-Small-Cell Lung
197
2026
1195
33.520
Why?
Lung Neoplasms
246
2026
2675
31.820
Why?
Protein Kinase Inhibitors
104
2026
983
13.140
Why?
Receptor Protein-Tyrosine Kinases
48
2025
227
10.200
Why?
Pyrimidines
50
2026
532
9.070
Why?
Antineoplastic Agents
80
2026
2219
8.920
Why?
Organophosphorus Compounds
21
2025
84
6.900
Why?
Proto-Oncogene Proteins c-met
26
2025
76
6.760
Why?
Pyrazoles
50
2026
517
6.650
Why?
Antineoplastic Combined Chemotherapy Protocols
53
2026
1998
6.520
Why?
ErbB Receptors
63
2026
636
6.200
Why?
Pyridines
38
2021
610
5.640
Why?
Gene Rearrangement
27
2026
156
4.940
Why?
Protein-Tyrosine Kinases
30
2026
429
4.330
Why?
Immunoconjugates
10
2025
138
4.100
Why?
Brain Neoplasms
32
2026
1325
3.900
Why?
Mutation
67
2026
4093
3.560
Why?
Drug Resistance, Neoplasm
36
2025
893
3.510
Why?
Acrylamides
19
2026
74
3.320
Why?
Proto-Oncogene Proteins
30
2026
616
3.190
Why?
Oncogenes
10
2025
113
3.150
Why?
Biomarkers, Tumor
30
2026
1339
3.050
Why?
Antibodies, Monoclonal, Humanized
27
2026
992
2.810
Why?
Carbazoles
14
2024
53
2.640
Why?
Humans
316
2026
146342
2.490
Why?
Aniline Compounds
15
2026
120
2.470
Why?
Neoplasms
32
2026
2954
2.470
Why?
Clinical Trials as Topic
19
2026
1064
2.460
Why?
Thoracic Neoplasms
4
2025
40
2.450
Why?
Middle Aged
157
2026
36619
2.360
Why?
Piperidines
13
2024
225
2.320
Why?
Aged
136
2026
26432
2.290
Why?
Small Cell Lung Carcinoma
15
2024
125
2.270
Why?
Proto-Oncogene Proteins p21(ras)
15
2025
250
2.070
Why?
Aged, 80 and over
73
2026
8391
2.040
Why?
Adenocarcinoma
16
2017
927
2.010
Why?
Molecular Targeted Therapy
16
2025
447
1.930
Why?
Antibodies, Monoclonal
23
2025
1512
1.930
Why?
Male
167
2026
73396
1.750
Why?
Female
169
2026
79499
1.690
Why?
Adult
122
2026
41087
1.640
Why?
Gene Amplification
11
2025
116
1.620
Why?
Quinazolines
12
2024
267
1.570
Why?
Medical Oncology
6
2026
345
1.560
Why?
Radiosurgery
13
2024
398
1.550
Why?
Oncogene Proteins, Fusion
9
2025
213
1.550
Why?
Lactams, Macrocyclic
10
2024
51
1.530
Why?
B7-H1 Antigen
9
2026
245
1.430
Why?
In Situ Hybridization, Fluorescence
15
2021
334
1.430
Why?
Indoles
20
2026
511
1.430
Why?
High-Throughput Nucleotide Sequencing
5
2025
539
1.410
Why?
Erlotinib Hydrochloride
13
2022
71
1.400
Why?
Pemetrexed
10
2026
40
1.400
Why?
Prognosis
35
2026
4351
1.390
Why?
Neoplasm Staging
32
2025
1488
1.360
Why?
Mesothelioma
5
2018
50
1.320
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
5
2013
31
1.320
Why?
Survival Rate
27
2026
2092
1.310
Why?
Lung Diseases, Interstitial
5
2022
677
1.280
Why?
Clinical Trials, Phase I as Topic
5
2024
49
1.240
Why?
Circulating Tumor DNA
6
2025
50
1.180
Why?
Central Nervous System
4
2021
278
1.170
Why?
Neoplasm Recurrence, Local
6
2025
1160
1.170
Why?
Retrospective Studies
46
2026
17438
1.150
Why?
Maximum Tolerated Dose
23
2026
217
1.140
Why?
Gene Dosage
4
2018
146
1.110
Why?
Disease-Free Survival
26
2020
778
1.110
Why?
Lactams
10
2024
28
1.090
Why?
Immunotherapy
7
2026
671
1.050
Why?
Cell Adhesion Molecules
3
2025
180
1.040
Why?
Cell-Free Nucleic Acids
4
2022
40
1.030
Why?
Treatment Outcome
47
2025
11821
1.020
Why?
Exons
13
2026
361
1.010
Why?
Imidazoles
4
2018
245
0.970
Why?
Trastuzumab
3
2022
119
0.970
Why?
Disease Progression
19
2025
2867
0.950
Why?
Camptothecin
5
2022
139
0.940
Why?
Piperazines
3
2019
368
0.940
Why?
Neoplasm Metastasis
13
2024
693
0.920
Why?
Cell Cycle
6
2012
595
0.880
Why?
Aminopyridines
10
2024
128
0.870
Why?
Apoptosis
8
2023
2439
0.860
Why?
Response Evaluation Criteria in Solid Tumors
6
2022
21
0.850
Why?
Follow-Up Studies
26
2024
5439
0.830
Why?
Proto-Oncogene Proteins c-ret
2
2021
41
0.800
Why?
DNA Copy Number Variations
7
2024
192
0.780
Why?
Antineoplastic Agents, Immunological
3
2025
200
0.780
Why?
Pleural Neoplasms
3
2018
31
0.780
Why?
Carboplatin
13
2026
168
0.760
Why?
Research Personnel
1
2025
190
0.750
Why?
Glomerular Filtration Rate
3
2019
745
0.740
Why?
Survival Analysis
12
2025
1378
0.730
Why?
Neuregulin-1
2
2021
50
0.730
Why?
Glutamates
7
2014
66
0.720
Why?
Pyridazines
3
2019
56
0.710
Why?
Guanine
7
2014
85
0.710
Why?
Paclitaxel
9
2020
260
0.710
Why?
Endpoint Determination
5
2018
84
0.700
Why?
Hypogonadism
2
2013
89
0.700
Why?
Dose-Response Relationship, Drug
13
2021
2022
0.660
Why?
ras Proteins
8
2014
148
0.650
Why?
Authorship
1
2021
51
0.640
Why?
Receptor, Fibroblast Growth Factor, Type 1
2
2018
59
0.640
Why?
Central Nervous System Neoplasms
5
2023
177
0.640
Why?
Patient Selection
5
2019
728
0.630
Why?
Carcinoma, Renal Cell
2
2013
231
0.610
Why?
Antigens, Neoplasm
4
2025
271
0.610
Why?
Biomarkers
8
2019
4340
0.590
Why?
Genomics
1
2025
853
0.580
Why?
Pneumonia
2
2022
635
0.580
Why?
Taxoids
6
2023
115
0.570
Why?
Kidney
2
2019
1498
0.570
Why?
Drug-Related Side Effects and Adverse Reactions
3
2020
266
0.570
Why?
Carcinoma, Large Cell
2
2025
17
0.560
Why?
Kaplan-Meier Estimate
15
2026
970
0.560
Why?
Proto-Oncogene Proteins B-raf
4
2018
231
0.550
Why?
Testosterone
2
2013
419
0.550
Why?
Drug Administration Schedule
11
2017
790
0.540
Why?
Mutagenesis, Insertional
4
2026
68
0.540
Why?
Kidney Neoplasms
2
2013
419
0.530
Why?
Cyclin-Dependent Kinases
2
2010
121
0.530
Why?
Thromboembolism
1
2018
129
0.520
Why?
RNA, Messenger
4
2025
2791
0.510
Why?
Pyrazines
2
2019
94
0.500
Why?
Creatinine
2
2019
511
0.490
Why?
Young Adult
23
2020
14330
0.490
Why?
Triazoles
3
2025
190
0.470
Why?
Healthcare Disparities
2
2021
733
0.470
Why?
Receptors, Fibroblast Growth Factor
2
2016
70
0.460
Why?
Kelch-Like ECH-Associated Protein 1
3
2025
15
0.460
Why?
Mouth Mucosa
2
2006
84
0.460
Why?
Hair
2
2006
81
0.450
Why?
Research Design
7
2026
1143
0.450
Why?
Etoposide
5
2024
169
0.450
Why?
Cranial Irradiation
7
2022
85
0.430
Why?
Liver Neoplasms
2
2019
776
0.420
Why?
Cohort Studies
14
2024
6077
0.420
Why?
Nitrofurantoin
1
2014
9
0.420
Why?
Anti-Infective Agents, Urinary
1
2014
16
0.410
Why?
Cystitis
1
2014
24
0.410
Why?
Signal Transduction
9
2026
5246
0.410
Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
23
0.400
Why?
Crown Ethers
1
2013
3
0.400
Why?
Meningeal Neoplasms
2
2026
95
0.380
Why?
Carcinoma, Squamous Cell
5
2019
628
0.380
Why?
Blood-Brain Barrier
2
2016
169
0.370
Why?
Cell Proliferation
9
2026
2502
0.370
Why?
Insulin-Like Growth Factor II
2
2009
24
0.370
Why?
Benzamides
3
2026
226
0.360
Why?
Smoking
2
2018
1486
0.360
Why?
Point Mutation
1
2013
232
0.360
Why?
Receptors, Platelet-Derived Growth Factor
1
2012
14
0.360
Why?
Clinical Trials, Phase II as Topic
2
2024
74
0.350
Why?
Organoplatinum Compounds
3
2012
65
0.350
Why?
Receptor, IGF Type 1
1
2012
64
0.350
Why?
Tissue Distribution
5
2020
334
0.350
Why?
Androgens
1
2013
179
0.340
Why?
Sulfonamides
5
2020
594
0.340
Why?
Translocation, Genetic
1
2012
127
0.330
Why?
Apoptosis Regulatory Proteins
1
2011
186
0.330
Why?
Cisplatin
5
2024
347
0.320
Why?
Keratin-18
1
2010
12
0.320
Why?
Cell Line, Tumor
12
2026
3545
0.320
Why?
Drug Therapy, Combination
1
2013
1036
0.320
Why?
Adenocarcinoma, Bronchiolo-Alveolar
2
2016
20
0.310
Why?
Adolescent
14
2022
22557
0.310
Why?
Estrenes
1
2010
12
0.310
Why?
Insulin-Like Growth Factor I
2
2009
320
0.310
Why?
Antimitotic Agents
1
2009
8
0.300
Why?
Lymphatic Metastasis
2
2009
335
0.300
Why?
Receptors, Somatomedin
1
2009
5
0.300
Why?
Chemoradiotherapy
3
2022
238
0.290
Why?
Caspase 3
1
2010
240
0.290
Why?
Antineoplastic Agents, Phytogenic
2
2001
178
0.290
Why?
Macrocyclic Compounds
2
2026
16
0.290
Why?
Estradiol
2
2010
517
0.290
Why?
Genetic Testing
3
2015
492
0.290
Why?
Lung
4
2019
4122
0.280
Why?
Catheter Ablation
1
2012
355
0.280
Why?
Genotype
5
2021
1879
0.280
Why?
Sulfones
4
2021
127
0.280
Why?
Mitosis
1
2009
195
0.280
Why?
Programmed Cell Death 1 Receptor
3
2019
268
0.270
Why?
Carcinoma, Neuroendocrine
2
2025
38
0.270
Why?
Lymph Node Excision
1
2009
174
0.270
Why?
Oligonucleotides, Antisense
1
2008
122
0.270
Why?
Immunohistochemistry
5
2022
1712
0.260
Why?
Antibodies, Bispecific
2
2026
70
0.260
Why?
HIV
1
2008
249
0.250
Why?
Cyclin-Dependent Kinase Inhibitor Proteins
1
2006
8
0.250
Why?
Administration, Oral
8
2015
872
0.250
Why?
Accidents
1
2007
43
0.240
Why?
Quality of Life
6
2025
3200
0.240
Why?
Quinazolinones
3
2016
18
0.240
Why?
Receptor, trkA
1
2026
17
0.240
Why?
Receptor, trkB
1
2026
39
0.240
Why?
Animals
21
2026
38107
0.240
Why?
Ethics, Medical
1
2006
90
0.230
Why?
Pharmacology
1
2005
10
0.230
Why?
Pharmacokinetics
1
2005
33
0.230
Why?
Technology, Pharmaceutical
1
2005
30
0.230
Why?
Registries
5
2024
2400
0.230
Why?
Indazoles
2
2026
86
0.230
Why?
Time Factors
7
2021
7109
0.220
Why?
Canada
2
2025
432
0.220
Why?
Tumor Microenvironment
3
2024
747
0.220
Why?
DNA, Neoplasm
2
2019
160
0.220
Why?
Karyopherins
1
2025
20
0.220
Why?
Cough
2
2017
123
0.210
Why?
Mortality
1
2007
375
0.210
Why?
Immunoenzyme Techniques
3
2014
197
0.200
Why?
Precision Medicine
4
2019
462
0.200
Why?
Pyrroles
4
2013
222
0.200
Why?
CTLA-4 Antigen
1
2024
105
0.200
Why?
Diarrhea
3
2026
190
0.200
Why?
Phenylurea Compounds
2
2016
122
0.200
Why?
Leukocytes, Mononuclear
1
2006
585
0.200
Why?
Prospective Studies
7
2023
8123
0.200
Why?
Cost-Benefit Analysis
3
2021
640
0.200
Why?
Membrane Glycoproteins
1
2026
495
0.200
Why?
Combined Modality Therapy
5
2017
1271
0.200
Why?
United States
8
2026
16136
0.190
Why?
Radiotherapy Dosage
3
2017
289
0.190
Why?
RNA
3
2019
926
0.190
Why?
Clinical Trials, Phase III as Topic
2
2024
116
0.190
Why?
Platinum
1
2023
48
0.190
Why?
Fertility
1
2024
174
0.180
Why?
Oligopeptides
1
2024
264
0.180
Why?
Tumor Burden
3
2018
326
0.180
Why?
NF-E2-Related Factor 2
1
2023
96
0.180
Why?
DNA Mutational Analysis
3
2019
410
0.180
Why?
Treatment Failure
3
2014
361
0.180
Why?
Carcinoma, Transitional Cell
1
2022
70
0.180
Why?
Benzodiazepinones
1
2021
18
0.170
Why?
Nails, Malformed
1
2001
5
0.170
Why?
Tomography, X-Ray Computed
5
2022
2786
0.170
Why?
Lymphoma, Follicular
1
2021
57
0.170
Why?
Carcinoma, Small Cell
1
2001
172
0.170
Why?
Fatigue
5
2015
363
0.160
Why?
Skin
1
2005
701
0.160
Why?
Biopsy
3
2013
1075
0.160
Why?
Neovascularization, Pathologic
3
2012
287
0.160
Why?
Epidermal Cyst
1
2000
13
0.160
Why?
Carcinogenesis
1
2022
226
0.160
Why?
Recurrence
3
2018
1133
0.160
Why?
Bevacizumab
2
2019
169
0.160
Why?
Retreatment
2
2017
79
0.160
Why?
Standard of Care
1
2020
81
0.150
Why?
Quality-Adjusted Life Years
2
2021
122
0.150
Why?
Pregnancy
2
2024
7230
0.150
Why?
Policy
1
2021
147
0.150
Why?
Radiodermatitis
1
2000
11
0.150
Why?
Breast Neoplasms
3
2020
2418
0.150
Why?
Proto-Oncogene Proteins c-bcl-2
2
2012
237
0.150
Why?
Oncogene Protein p21(ras)
1
2019
11
0.150
Why?
Deglutition Disorders
1
2001
159
0.150
Why?
Suicide
1
2007
647
0.150
Why?
Consolidation Chemotherapy
1
2019
11
0.150
Why?
Positron-Emission Tomography
4
2014
343
0.150
Why?
Organs at Risk
1
2019
37
0.150
Why?
Urinary Bladder Neoplasms
1
2022
259
0.150
Why?
Diagnostic Imaging
1
2022
340
0.150
Why?
Aminoquinolines
1
2019
18
0.140
Why?
Carcinoma, Lewis Lung
1
2019
16
0.140
Why?
Vascular Endothelial Growth Factor A
3
2012
545
0.140
Why?
Oncogene Proteins
1
2019
61
0.140
Why?
Radiotherapy, Conformal
2
2017
75
0.140
Why?
Gene Fusion
1
2018
31
0.140
Why?
Lymphoma, B-Cell
1
2000
150
0.140
Why?
Antinematodal Agents
1
2018
7
0.140
Why?
Incidence
3
2020
2936
0.140
Why?
Motivation
1
2023
605
0.140
Why?
Prevalence
1
2025
2861
0.140
Why?
CD8-Positive T-Lymphocytes
1
2025
931
0.140
Why?
Gold
1
2019
118
0.140
Why?
Multivariate Analysis
2
2019
1543
0.140
Why?
Drug Approval
1
2018
94
0.140
Why?
Radiotherapy
3
2016
209
0.130
Why?
Lymphoma, Large B-Cell, Diffuse
1
2000
195
0.130
Why?
Cytotoxicity, Immunologic
1
2018
224
0.130
Why?
MAP Kinase Signaling System
1
2019
307
0.130
Why?
Immunity, Cellular
1
2019
277
0.130
Why?
Drowning
1
2017
7
0.130
Why?
Chemotherapy, Adjuvant
3
2022
429
0.130
Why?
Diagnosis, Differential
2
2014
1503
0.130
Why?
Proportional Hazards Models
3
2020
1331
0.130
Why?
Receptors, Growth Factor
3
2011
52
0.120
Why?
Thymus Neoplasms
1
2017
30
0.120
Why?
Thymoma
1
2017
38
0.120
Why?
Benzimidazoles
3
2018
191
0.120
Why?
Scotland
2
2007
54
0.120
Why?
Nausea
1
2017
111
0.120
Why?
Real-Time Polymerase Chain Reaction
2
2014
334
0.120
Why?
Pleural Effusion, Malignant
1
2016
12
0.120
Why?
Hospitalization
1
2007
2475
0.120
Why?
Head and Neck Neoplasms
1
2021
563
0.120
Why?
Adjuvants, Immunologic
1
2017
245
0.120
Why?
Headache
1
2017
150
0.120
Why?
Decision Trees
1
2016
76
0.120
Why?
Centrosome
1
2016
67
0.120
Why?
Markov Chains
1
2016
129
0.110
Why?
Proto-Oncogene Proteins c-kit
1
2016
73
0.110
Why?
Xenograft Model Antitumor Assays
4
2024
930
0.110
Why?
Chronic Disease
2
2014
1827
0.110
Why?
Peritoneal Neoplasms
1
2016
103
0.110
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2014
974
0.110
Why?
Risk Assessment
5
2015
3712
0.110
Why?
Radiotherapy, Adjuvant
2
2022
222
0.110
Why?
Drug Interactions
2
2013
405
0.110
Why?
Mice
9
2026
18297
0.110
Why?
Postoperative Care
1
2017
301
0.110
Why?
Neutropenia
4
2019
153
0.110
Why?
Structure-Activity Relationship
2
2018
563
0.100
Why?
Cryptogenic Organizing Pneumonia
1
2014
20
0.100
Why?
Randomized Controlled Trials as Topic
2
2018
1763
0.100
Why?
Australia
2
2012
291
0.100
Why?
Thoracic Surgery, Video-Assisted
1
2014
55
0.100
Why?
Brain
3
2024
2991
0.100
Why?
Sequence Analysis, DNA
2
2014
771
0.100
Why?
Vascular Endothelial Growth Factor Receptor-2
2
2013
87
0.100
Why?
Magnetic Resonance Imaging
5
2018
3926
0.100
Why?
Periodicals as Topic
1
2016
214
0.100
Why?
Reproducibility of Results
3
2006
3416
0.100
Why?
Threonine
1
2013
43
0.100
Why?
Membrane Proteins
2
2025
1130
0.100
Why?
Genetic Predisposition to Disease
2
2018
2488
0.100
Why?
Skin Neoplasms
1
2000
806
0.100
Why?
Sex Hormone-Binding Globulin
1
2013
51
0.090
Why?
Disease Management
2
2020
651
0.090
Why?
Ipilimumab
2
2026
44
0.090
Why?
HSP90 Heat-Shock Proteins
1
2013
47
0.090
Why?
HIV Infections
1
2008
3215
0.090
Why?
Sodium-Phosphate Cotransporter Proteins, Type IIb
1
2012
8
0.090
Why?
GTP Phosphohydrolases
1
2013
95
0.090
Why?
Focal Adhesion Kinase 2
1
2012
4
0.090
Why?
Serum Albumin
1
2013
147
0.090
Why?
Methionine
1
2013
160
0.090
Why?
Thiophenes
1
2013
117
0.090
Why?
Luteinizing Hormone
1
2013
206
0.090
Why?
Dyspnea
1
2014
251
0.090
Why?
Heterozygote
1
2013
311
0.090
Why?
Focal Adhesion Kinase 1
1
2012
32
0.090
Why?
Genes, ras
1
2012
70
0.090
Why?
Blotting, Western
2
2014
1177
0.090
Why?
Biomedical Research
2
2010
729
0.090
Why?
Platelet-Derived Growth Factor
1
2012
85
0.090
Why?
Biological Transport
1
2013
424
0.090
Why?
Hydroxamic Acids
1
2012
96
0.090
Why?
Biomarkers, Pharmacological
1
2011
26
0.090
Why?
Quinolines
1
2013
191
0.090
Why?
Radiation Pneumonitis
1
2011
31
0.080
Why?
Follicle Stimulating Hormone
1
2013
265
0.080
Why?
Electronic Health Records
2
2024
1210
0.080
Why?
Models, Molecular
2
2018
1574
0.080
Why?
Lymphocytes, Tumor-Infiltrating
2
2025
156
0.080
Why?
Phytotherapy
1
2011
74
0.080
Why?
Vimentin
1
2011
47
0.080
Why?
Area Under Curve
2
2012
335
0.080
Why?
Immunosuppressive Agents
1
2016
829
0.080
Why?
Niacinamide
1
2012
103
0.080
Why?
Genes, bcl-2
1
2011
21
0.080
Why?
Hyperglycemia
1
2015
384
0.080
Why?
Induction Chemotherapy
1
2011
87
0.080
Why?
Fluorouracil
2
2012
231
0.080
Why?
Heterogeneous-Nuclear Ribonucleoprotein L
1
2010
2
0.080
Why?
Rats
2
2010
5586
0.080
Why?
Caspase 9
1
2010
54
0.080
Why?
Heptanoic Acids
1
2011
67
0.080
Why?
X-Linked Inhibitor of Apoptosis Protein
1
2010
9
0.080
Why?
Gene Expression Regulation, Neoplastic
3
2025
1432
0.080
Why?
Glioma
1
2015
425
0.080
Why?
Amino Acid Chloromethyl Ketones
1
2010
24
0.080
Why?
Deoxycytidine
2
2011
219
0.080
Why?
Cysteine Proteinase Inhibitors
1
2010
48
0.080
Why?
In Situ Nick-End Labeling
1
2010
120
0.080
Why?
Histone Deacetylase Inhibitors
1
2012
219
0.080
Why?
Transplantation, Heterologous
1
2010
165
0.080
Why?
Neoplasm Transplantation
1
2010
238
0.080
Why?
Caspase Inhibitors
1
2010
81
0.080
Why?
Immunoblotting
1
2010
294
0.080
Why?
Gene Frequency
2
2026
496
0.080
Why?
Alcohol Drinking
1
2017
850
0.080
Why?
Cadherins
1
2011
202
0.080
Why?
Multicenter Studies as Topic
1
2011
417
0.080
Why?
Protein Structure, Tertiary
1
2012
834
0.070
Why?
Insulin-Like Growth Factor Binding Proteins
1
2009
26
0.070
Why?
RNA Precursors
1
2010
155
0.070
Why?
Pharmacogenetics
1
2010
176
0.070
Why?
Cannabinoids
1
2011
182
0.070
Why?
Epithelial-Mesenchymal Transition
1
2011
219
0.070
Why?
Demography
1
2010
274
0.070
Why?
Species Specificity
1
2010
543
0.070
Why?
Cognition
2
2016
1292
0.070
Why?
RNA Interference
1
2010
472
0.070
Why?
Anemia
2
2026
190
0.070
Why?
Alternative Splicing
1
2010
253
0.070
Why?
Dogs
1
2010
517
0.070
Why?
Floxuridine
1
2008
5
0.070
Why?
Marijuana Smoking
1
2011
249
0.070
Why?
Weight Loss
1
2014
858
0.070
Why?
Enzyme-Linked Immunosorbent Assay
1
2010
846
0.070
Why?
Protein Kinase C beta
1
2008
21
0.070
Why?
Medical Records
1
2009
193
0.070
Why?
Angiogenesis Inhibitors
1
2010
239
0.070
Why?
Radiotherapy Planning, Computer-Assisted
1
2009
150
0.070
Why?
Polymerase Chain Reaction
1
2011
1031
0.070
Why?
Capecitabine
1
2008
56
0.070
Why?
Practice Guidelines as Topic
1
2016
1591
0.070
Why?
Risk Factors
4
2019
10921
0.060
Why?
Double-Blind Method
2
2016
2070
0.060
Why?
TNF-Related Apoptosis-Inducing Ligand
1
2007
54
0.060
Why?
Sensitivity and Specificity
2
2018
1998
0.060
Why?
Salvage Therapy
2
2019
166
0.060
Why?
Everolimus
2
2020
112
0.060
Why?
Clinical Decision-Making
2
2022
365
0.060
Why?
Antibiotics, Antineoplastic
1
2008
141
0.060
Why?
Retinoblastoma Protein
1
2006
63
0.060
Why?
Scalp
1
2006
38
0.060
Why?
Protein Kinase C
1
2008
250
0.060
Why?
Placebos
1
2006
192
0.060
Why?
Receptors, Vascular Endothelial Growth Factor
1
2006
109
0.060
Why?
Tumor Suppressor Protein p53
1
2010
530
0.060
Why?
Cell Line
1
2012
2814
0.060
Why?
Neoplasm Proteins
1
2009
444
0.060
Why?
Receptors, Estrogen
1
2008
406
0.060
Why?
Trypsin Inhibitor, Kazal Pancreatic
1
2025
6
0.060
Why?
Hair Follicle
1
2005
35
0.060
Why?
Health Services Accessibility
1
2014
1107
0.060
Why?
Cetuximab
2
2017
110
0.060
Why?
Melanocytes
1
2005
57
0.060
Why?
Tumor Cells, Cultured
2
2019
882
0.060
Why?
Pyrrolidines
1
2026
127
0.060
Why?
Brain-Derived Neurotrophic Factor
1
2026
155
0.060
Why?
Reference Values
1
2006
796
0.050
Why?
Hydrazines
1
2025
37
0.050
Why?
Monocytes
1
2008
538
0.050
Why?
Oncolytic Virotherapy
1
2024
13
0.050
Why?
Colorectal Neoplasms
1
2013
874
0.050
Why?
Safety
1
2006
347
0.050
Why?
Models, Biological
1
2012
1761
0.050
Why?
Genes, Tumor Suppressor
1
2024
84
0.050
Why?
Cannabis
1
2011
521
0.050
Why?
Nitric Oxide Synthase Type II
1
2024
162
0.050
Why?
Risk
1
2007
920
0.050
Why?
Cross-Over Studies
1
2006
615
0.050
Why?
Class I Phosphatidylinositol 3-Kinases
2
2014
111
0.050
Why?
Adenoviridae
1
2024
197
0.050
Why?
Specimen Handling
1
2005
178
0.050
Why?
Phosphorylation
1
2008
1724
0.050
Why?
Delivery of Health Care
1
2010
947
0.050
Why?
Genetic Vectors
1
2024
327
0.050
Why?
5'-Nucleotidase
1
2023
49
0.050
Why?
Intracellular Signaling Peptides and Proteins
1
2025
457
0.050
Why?
MAP Kinase Kinase 1
2
2014
70
0.050
Why?
Phosphatidylinositol 3-Kinases
2
2014
384
0.040
Why?
Tumor Suppressor Proteins
1
2024
315
0.040
Why?
Societies, Medical
1
2026
907
0.040
Why?
Pharyngeal Diseases
1
2001
17
0.040
Why?
Esophageal Diseases
1
2001
29
0.040
Why?
Heparin, Low-Molecular-Weight
1
2021
37
0.040
Why?
Opportunistic Infections
1
2001
47
0.040
Why?
Asia
1
2021
69
0.040
Why?
Mediastinal Neoplasms
1
2001
54
0.040
Why?
United States Food and Drug Administration
1
2022
208
0.040
Why?
Mice, SCID
2
2013
360
0.040
Why?
Ligands
1
2023
678
0.040
Why?
Gastrointestinal Neoplasms
1
2001
74
0.040
Why?
Brain Stem Neoplasms
1
2001
86
0.040
Why?
Drug Combinations
1
2022
400
0.040
Why?
Sex Characteristics
1
2006
801
0.040
Why?
Neoplasms, Second Primary
1
2001
103
0.040
Why?
Carbon Monoxide
1
2020
82
0.040
Why?
Consensus
1
2022
467
0.040
Why?
Thrombocytopenia
2
2012
206
0.040
Why?
Europe
1
2021
421
0.040
Why?
Surveys and Questionnaires
1
2013
6073
0.040
Why?
Focal Adhesion Protein-Tyrosine Kinases
1
2019
34
0.040
Why?
Comparative Effectiveness Research
1
2020
171
0.040
Why?
Age Factors
1
2007
3347
0.040
Why?
Tuberculosis, Pulmonary
1
2000
127
0.040
Why?
Lymphopenia
1
2019
62
0.040
Why?
Leukocyte Count
1
2019
321
0.030
Why?
Liquid Biopsy
1
2018
16
0.030
Why?
Genes, erbB-1
1
2018
21
0.030
Why?
Radiotherapy, Intensity-Modulated
1
2019
143
0.030
Why?
Immune System
1
2019
181
0.030
Why?
Genome, Human
1
2000
431
0.030
Why?
DNA Topoisomerases, Type I
1
2017
15
0.030
Why?
Radiation Dosage
1
2019
193
0.030
Why?
Topoisomerase I Inhibitors
1
2017
20
0.030
Why?
Intention to Treat Analysis
1
2017
78
0.030
Why?
Lymphocytes
1
2019
379
0.030
Why?
Practice Patterns, Physicians'
1
2006
1408
0.030
Why?
Organoids
1
2019
143
0.030
Why?
Hyperphosphatemia
1
2016
15
0.030
Why?
Exosomes
1
2018
104
0.030
Why?
Exanthema
1
2017
86
0.030
Why?
Mice, Inbred BALB C
1
2019
1244
0.030
Why?
Drug Monitoring
1
2020
399
0.030
Why?
Feasibility Studies
1
2020
1135
0.030
Why?
T-Lymphocytes
1
2024
2012
0.030
Why?
Myalgia
1
2015
13
0.030
Why?
Genetic Heterogeneity
1
2016
67
0.030
Why?
Drug Therapy
1
2016
85
0.030
Why?
Karnofsky Performance Status
1
2015
37
0.030
Why?
Creatine Kinase
1
2015
70
0.030
Why?
Aspartate Aminotransferases
1
2015
86
0.030
Why?
Heart
1
2019
626
0.030
Why?
Observational Studies as Topic
1
2016
133
0.030
Why?
Alanine Transaminase
1
2015
151
0.030
Why?
Edema
1
2015
131
0.030
Why?
Constipation
1
2015
98
0.030
Why?
Gonanes
1
2014
23
0.030
Why?
Palliative Care
2
2014
1032
0.030
Why?
Proto-Oncogenes
1
2014
27
0.030
Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2014
143
0.030
Why?
Texas
1
2014
280
0.020
Why?
Multiplex Polymerase Chain Reaction
1
2014
56
0.020
Why?
Leukopenia
1
2013
33
0.020
Why?
Amino Acid Substitution
1
2014
297
0.020
Why?
Neutrophils
1
2019
1133
0.020
Why?
Epidermal Growth Factor
1
2013
157
0.020
Why?
United Kingdom
1
2014
377
0.020
Why?
Computational Biology
1
2018
678
0.020
Why?
Inhibitory Concentration 50
1
2013
90
0.020
Why?
PTEN Phosphohydrolase
1
2014
166
0.020
Why?
Recombination, Genetic
1
2014
202
0.020
Why?
Syndecan-4
1
2012
6
0.020
Why?
Vision Disorders
1
2014
179
0.020
Why?
Guidelines as Topic
1
2014
267
0.020
Why?
Antigens, Differentiation, B-Lymphocyte
1
2012
36
0.020
Why?
Pyrimidinones
1
2013
124
0.020
Why?
Metabolic Clearance Rate
1
2012
115
0.020
Why?
Proto-Oncogene Proteins c-akt
1
2014
441
0.020
Why?
Leucovorin
1
2012
98
0.020
Why?
Sirolimus
1
2013
282
0.020
Why?
Cytochrome P-450 CYP3A Inhibitors
1
2012
18
0.020
Why?
Midazolam
1
2012
69
0.020
Why?
Nonlinear Dynamics
1
2012
96
0.020
Why?
Biological Availability
1
2011
146
0.020
Why?
Cytochrome P-450 CYP3A
1
2012
93
0.020
Why?
Mice, Nude
1
2013
668
0.020
Why?
Genetic Association Studies
1
2013
379
0.020
Why?
Mutation, Missense
1
2013
334
0.020
Why?
Receptor, ErbB-4
1
2011
19
0.020
Why?
Pyridones
1
2013
210
0.020
Why?
Radiopharmaceuticals
1
2012
210
0.020
Why?
Fluorodeoxyglucose F18
1
2012
164
0.020
Why?
Silencer Elements, Transcriptional
1
2010
1
0.020
Why?
Databases, Factual
1
2017
1493
0.020
Why?
Histocompatibility Antigens Class II
1
2012
365
0.020
Why?
Cell Survival
1
2013
1105
0.020
Why?
MAP Kinase Kinase 2
1
2010
28
0.020
Why?
Molecular Diagnostic Techniques
1
2011
104
0.020
Why?
Capsules
1
2010
40
0.020
Why?
Meta-Analysis as Topic
1
2011
173
0.020
Why?
Isoenzymes
1
2010
294
0.020
Why?
Serine Endopeptidases
1
2010
129
0.020
Why?
Socioeconomic Factors
1
2014
1327
0.020
Why?
Microtubule-Associated Proteins
1
2010
187
0.020
Why?
Alopecia
1
2009
33
0.020
Why?
Vascular Endothelial Growth Factor Receptor-1
1
2010
74
0.020
Why?
Infusions, Intravenous
1
2010
432
0.020
Why?
Precancerous Conditions
1
2010
162
0.020
Why?
Enzyme Inhibitors
1
2012
823
0.020
Why?
RNA, Small Interfering
1
2010
633
0.020
Why?
Evidence-Based Medicine
1
2012
731
0.020
Why?
Substrate Specificity
1
2008
389
0.020
Why?
Mice, Inbred C57BL
1
2019
6034
0.020
Why?
Hormone Replacement Therapy
1
2008
107
0.020
Why?
Cell Cycle Proteins
1
2010
630
0.010
Why?
California
1
2008
475
0.010
Why?
Neoplastic Stem Cells
1
2010
403
0.010
Why?
Pain
1
2011
790
0.010
Why?
DNA Repair
1
2008
255
0.010
Why?
DNA Damage
1
2008
439
0.010
Why?
Early Detection of Cancer
1
2010
506
0.010
Why?
Colorado
1
2014
4595
0.010
Why?
MicroRNAs
1
2010
699
0.010
Why?
Genome-Wide Association Study
1
2010
1537
0.010
Why?
Predictive Value of Tests
1
2008
2113
0.010
Why?
Gambia
1
2000
8
0.010
Why?
Chromosomes, Human, Pair 15
1
2000
50
0.010
Why?
X Chromosome
1
2000
66
0.010
Why?
Nuclear Family
1
2000
51
0.010
Why?
Genetic Linkage
1
2000
271
0.010
Why?
Microsatellite Repeats
1
2000
159
0.010
Why?
Genetic Markers
1
2000
340
0.010
Why?
South Africa
1
2000
262
0.010
Why?
Chromosome Mapping
1
2000
508
0.010
Why?
Camidge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)